Mark Alvino
Known title: DirectorCIK: 0001356828
Associated companies
Transaction History
| ABEO | ▼ Sell | Open Market | 15,000 | $88K | 9/1/2026 | View on chart |
| ABEO | ▼ Sell | Gift | 500 | $0 | 5/26/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 6,500 | $35K | 5/22/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 2,000 | $10K | 2/2/2026 | View on chart |
| ABEO | ▲ Buy | Grant | 37,313 | $0 | 1/26/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 13,500 | $71K | 1/21/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 15,000 | $71K | 11/13/2025 | View on chart |
| ABEO | ▼ Sell | Open Market | 13,093 | $77K | 7/9/2025 | View on chart |
| ABEO | ▼ Sell | Open Market | 2,000 | $13K | 5/27/2025 | View on chart |
| ABEO | ▼ Sell | Open Market | 8,000 | $45K | 5/16/2025 | View on chart |
| ABEO | ▲ Buy | Grant | 36,101 | $0 | 1/31/2025 | View on chart |
| ABEO | ▼ Sell | Open Market | 4,000 | $22K | 1/29/2025 | View on chart |
| ABEO | ▼ Sell | Open Market | 4,000 | $20K | 1/21/2025 | View on chart |
| ABEO | ▲ Buy | Grant | 11,797 | $0 | 8/26/2024 | View on chart |
| ABEO | ▲ Buy | Grant | 23,611 | $0 | 7/8/2024 | View on chart |
| ABEO | ▼ Sell | Open Market | 25,890 | $117K | 6/18/2024 | View on chart |
| ABEO | ▼ Sell | Open Market | 7,084 | $36K | 1/17/2024 | View on chart |
| ABEO | ▼ Sell | Open Market | 6,316 | $25K | 9/27/2023 | View on chart |
| ABEO | ▲ Buy | Grant | 58,689 | $271K | 6/14/2023 | View on chart |
| ABEO | ▼ Sell | Open Market | 887 | $3K | 4/25/2023 | View on chart |
| ABEO | ▲ Buy | Grant | 13,400 | $0 | 9/26/2022 | View on chart |
| ABEO | ▼ Sell | Open Market | 20,000 | $3K | 6/15/2022 | View on chart |
| ABEO | ▼ Sell | Open Market | 35,000 | $5K | 6/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth
Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth. Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.